Preliminary Safety and Efficacy of XT-150 in Facet Joint Osteoarthritis

Osteoarthritis, Spine Clinical Trial

Official title:
A Placebo-controlled, Double-blind Evaluation of Safety, Tolerability, and Efficacy of XT-150 for the Treatment of Facet Joint Osteoarthritis Pain

Status Withdrawn

Clinical Trial Summary

Preliminary safety and efficacy of XT-150 in the synovial capsule of osteoarthritic facet joints in the vertebra of the spine.

Clinical Trial Description

This is a Phase 1, safety and efficacy study of XT-150 in adult participants experiencing back pain due to inflammation of the facet joint osteoarthritis (FJOA) and who are eligible for intra-synovial glucocorticoid injection, or radiofrequency ablation of medial branches of the primary dorsal ramus of the exiting nerve root, which innervates the adjacent facet joints. ;

Study Design

Related Conditions & MeSH terms

Clinical Trial Details

NCT number	NCT04841512
Study type	Interventional
Source	Xalud Therapeutics, Inc.
Contact
Status	Withdrawn
Phase	Phase 1/Phase 2
Start date	October 2021
Completion date	March 1, 2022

View Details

See also
Status	Clinical Trial	Phase
Recruiting	`NCT03076658` - Open Access Database of Standing Full Body Radiographs in Asymptomatic Volunteers	N/A
Recruiting	`NCT05852808` - Evaluation of Pain Level Reduction After Low-dose Radiation in Symptomatic Facet Joint Arthritis	N/A
Recruiting	`NCT04137835` - Non-invasive Evaluation of Upper and Lower Body Function With Showmotion	N/A